PDF(Pubmed)
Abstract：
Killer cell lectin-like receptor G1 (KLRG1) is an immune checkpoint receptor expressed predominantly in NK and T-cell subsets that downregulates the activation and proliferation of immune cells and participates in cell-mediated immune responses. Accumulating evidence has demonstrated the importance of KLRG1 as a noteworthy disease marker and therapeutic target that can influence disease onset, progression, and prognosis. Blocking KLRG1 has been shown to effectively mitigate the effects of downregulation in various mouse tumor models, including solid tumors and hematologic malignancies. However, KLRG1 inhibitors have not yet been approved for human use, and the understanding of KLRG1 expression and its mechanism of action in various diseases remains incomplete. In this review, we explore alterations in the distribution, structure, and signaling pathways of KLRG1 in immune cells and summarize its expression patterns and roles in the development and progression of autoimmune diseases, infectious diseases, and cancers. Additionally, we discuss the potential applications of KLRG1 as a tool for tumor immunotherapy.
摘要：
杀伤细胞凝集素样受体G1(KLRG1)是主要在NK和T细胞亚群中表达的免疫检查点受体,其下调免疫细胞的活化和增殖并参与细胞介导的免疫应答。越来越多的证据表明，KLRG1作为一个值得注意的疾病标志物和治疗靶点的重要性，可以影响疾病的发作。programming,和预后。阻断KLRG1已被证明可以有效减轻各种小鼠肿瘤模型的下调效应，包括实体瘤和血液恶性肿瘤。然而,KLRG1抑制剂尚未被批准用于人类使用，对KLRG1的表达及其在各种疾病中的作用机制的认识尚不完全。在这次审查中,我们探索分布的变化，结构,和KLRG1在免疫细胞中的信号通路,并总结其在自身免疫性疾病发生发展中的表达模式和作用,传染病,和癌症。此外,我们讨论了KLRG1作为肿瘤免疫治疗工具的潜在应用。
